Is Clover Health Investments, Corp. (CLOV) the Best Multibagger Stock to Buy in 2025?
March 13, 2025
We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at where Clover Health Investments, Corp. (NASDAQ:CLOV) stands against other best multibagger stocks to buy in 2025.
In the world of investing, the term “multibagger” refers to stocks that have the potential to deliver returns several times greater than the original investment. One key factor that can help identify potential multibaggers is momentum. Momentum investing focuses on capitalizing on the continuation of existing market trends. Investors using this strategy look for stocks that are experiencing upward price movements, often driven by strong earnings reports, positive news, industry tailwinds, or overall market sentiment. The idea is simple: “the trend is your friend,” and momentum can be a powerful force in identifying winners before they peak. The importance of momentum has been recognized by famous investors, but many of them emphasized the idea that it is crucial to catch momentum stocks early on. As Warren Buffett put it – “What the wise do in the beginning, fools do in the end”.
READ ALSO: 12 Best Multibagger Penny Stocks to Buy Now
The US market is close to entering a correction mode as the absolute magnitude of decline since the mid-February peak is approaching 10%. The current policies of the new US administration, such as tariffs, federal jobs cuts and cuts in some large-scale public projects, are causing havoc among investors as many are fearing a scenario in which the US economy enters stagflation – a period of high inflation among weak economic growth and unemployment. Some analysts have pointed out that sectors reliant on government contracts, such as infrastructure and defense, are already experiencing heightened volatility as a result of these policy shifts. In a recent interview with Maria Bartiromo on Fox News, the President himself refused to rule out a recession in the current year and claimed that the economy is in “a period of transition” and that tariffs might fuel inflation at some point. With consumer confidence showing early signs of weakening, as signaled by recent business surveys, some economists argue that the Federal Reserve may be forced to intervene sooner than expected to stabilize the markets. This idea was already supported by the President, who at some point expressed the opinion that interest rates in the US economy are higher than they should be.
The aforementioned developments have caused a market selloff, particularly in previously high-momentum stocks such as the Magnificent 8, which have benefited from the AI megatrend and were responsible for most of the market returns last year. Prior to that, many previously well-performing stocks, such as government contractors, had already lost their momentum following the election results, while some of the few well-performing healthcare stocks were hit by Medicare/Medicaid reimbursement threats. Likewise, the energy sector remained somewhat out of favor – despite volume tailwinds from Trump 2.0, the expectation of lower oil prices amid a weaker economy has put downward pressure on stock prices in the sector. The key takeaway for investors is that one should look for multibaggers that haven’t yet lost their momentum during the market dip in the last month. These are often lower-capitalization companies that are underfollowed by analysts and operate in high-growth markets.
To compile our list of multibagger stocks, we used Finviz to filter the companies that have delivered at least 200% stock price return in the last twelve months. Then we compare the list with our proprietary database of hedge funds ownership as of Q4 2024 and include in the article the top 12 names with the highest number of hedge funds that own the stock.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic.
Number of Hedge Fund Holders: 21
Stock Price Return in the last twelve months: 353%
Clover Health Investments, Corp. (NASDAQ:CLOV) is a healthcare technology company that provides Medicare Advantage insurance plans. It leverages its proprietary Clover Assistant platform, an AI-driven software designed to improve clinical decision-making and patient outcomes. The company serves Medicare-eligible individuals, offering plans with low costs and broad provider networks. CLOV operates primarily in the United States, focusing on data-driven healthcare management to enhance efficiency and preventative care.
The year 2024 was pivotal for Clover Health Investments, Corp. (NASDAQ:CLOV), marked by achieving meaningful full year adjusted EBITDA profitability and strong membership growth. The company surpassed 100,000 Medicare Advantage members with a 27% YoY growth and achieved a 95% AEP retention rate. The company strengthened its star ratings with over 95% of members now in 4-star rated PPO plans for the 2025 star rating year, which will positively impact financials in 2026. CLOV successfully launched Counterpart Health, its software business housing Clover Assistant for third-party partnerships, signing and implementing its first external partners.
For 2025, Clover Health Investments, Corp. (NASDAQ:CLOV) expects revenue between $1.8 billion and $1.875 billion, reflecting 37% YoY growth at the midpoint, with Medicare Advantage membership projected to grow 30%. The company’s technology-first care model has demonstrated strong results, with Clover Assistant delivering over 1,000 basis points of MCR improvement for returning MA members whose PCPs use CA compared to those who do not. Looking ahead to 2026, CLOV is positioned for accelerated profitability due to its 4-star payment status, maturing member cohort economics, and increased impact of cost efficiency programs. With a 353% stock price return in the last twelve months, CLOV is one of the best multibagger stocks to buy in 2025.
Overall, CLOV ranks 8th on our list of best multibagger stocks to buy in 2025. While we acknowledge the potential of CLOV as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CLOV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy
Search
RECENT PRESS RELEASES
Related Post